Added to YB: 2024-06-03
Pitch date: 2024-05-25
ABBV [bullish]
AbbVie Inc.
+40.3%
current return
Author Info
Disruptive Analytics has 30+ years of experience as a retail investor and is now fully engaged in managing their own money. Sign up for the newsletter.
Company Info
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
Market Cap
$369.4B
Pitch Price
$147.32
Price Target
188.47 (-9%)
Dividend
3.31%
EV/EBITDA
14.59
P/E
88.49
EV/Sales
7.07
Sector
Biotechnology
Category
value
AbbVie Inc. - $ABBV
ABBV: Strong portfolio & pipeline expand moat in arthritis, botox, oncology. Excels at M&A, bolstering neuroscience & next-gen cancer treatments. 20% upside despite bull run; massive FCF & dividend pay to wait for gains. Election may bring short-term healthcare jitters.
Read full article (3 min)